Permax ( Pergolide ) Puts Parkinson's Patients at risk of valvular heart disease
January 3, 2007 - The New England Journal of Medicine published two studies today that indicate Permax ( Pergolide ) raises the risk of valvular heart damage in Parkinson's patients between 7 and 35 times when compared to other therapies. Pergolide is also used to treat restless leg syndrome. The drugs apparently activate the 5-HT2b cellular receptor which can cause heart valve damage and lead to heart failure and sudden death.
If you or a loved one has taken Permax ( Pergolide ) and been diagnosed with valvular heart disease ( VHD ) you should call us toll free now at 1-866-374-0338 because you may be entitled to compensation from the manufacturer of Permax.
Get your free, no obligation claim review by a lawyer today.
Call us at toll free 1-866-374-0338,
use the Free Claim Evaluation form to your right, or
click on Live Support on the right of this page.
We have represented clients in every state and helped thousands of injured clients nationwide make recoveries for their injuries. We are ready to help you! Our clients are never at risk of paying any fees, expenses, or costs out of pocket. All fees costs and expenses are paid only out of any recovery we make for you.
Do not delay. Contact us now to find out if we can help. The claim evaluation is free. All claims have strict time limitations which will bar any recovery you or your loved may be entitled if the claim is not brought on time.
CALL NOW 1-866-374-0338
Appointments with lawyers available nationwide. Principal office Fort Worth, TX
Pergolide (marketed as Permax)
The FDA is notifying you that the companies that manufacture and distribute pergolide have agreed to withdraw this drug from the market due to the potential for heart valve damage. Two new studies showed that patients with Parkinson’s disease who were treated with pergolide had an increased chance of serious damage to their heart valves when compared to patients who did not receive the drug. Pergolide is a member of a class of drugs known as dopamine agonists and is used with levodopa and carbidopa to manage the signs and symptoms (tremors and slowness of movement) of Parkinson’s disease.
Patients with Parkinson’s disease who are taking pergolide should:
Contact their healthcare professional to discuss alternate treatment options.
NOT stoptakingPergolide without consulting their healthcare professional, since stopping pergolide too quickly can be dangerous and several other effective treatments are available.
Healthcare professionals who prescribe pergolide should consider the following:
The U.S. Food and Drug Administration (FDA) today announced that manufacturers of pergolide drug products, which are used to treat Parkinson’s disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients’ heart valves.
The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of pergolide manufactured by Par and Teva. Pergolide is in a class of medications called dopamine agonists and is used with levodopa and carbidopa to manage the symptoms (tremors and slowness of movement) of Parkinson’s disease.
In 2006, an estimated 12,000 patients received prescriptions for pergolide from retail pharmacies in the United States. Patients taking pergolide should contact their doctors to discuss alternate treatments. Patients should not stop taking the medication, as stopping pergolide abruptly can be dangerous.
Permax 
Permax ( Pergolide ) Puts Parkinson's Patients at risk of valvular heart disease 
